Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKSE: 6990) is trading at HK$467.00, about ₹5,714 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, up 0.21% today. Indian residents can buy Sichuan Kelun-Biotech Biopharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$463.00
Today's high
HK$483.80
52 week low
HK$339.60
52 week high
HK$581.00
6990 opened at HK$466.60, closed previously at HK$466.00, and has traded between HK$339.60 and HK$581.00 over the past 52 weeks.
About
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Key statistics
Avg. volume
963.77K
Market cap
HK$108.90B
P/E Ratio
725.46
Price-to-sales ratio
42.30
Enterprise value
CN¥90.36B
Free cash flow yield
0.46%
Debt-to-equity ratio
0.02
Return on equity
2.43%
ROIC
-3.11%
Beta
-0.03
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥2.06B
Earnings per share
-CN¥1.66
Free cash flow
-CN¥306.55M
Net profit margin
5.77%
Gross margin
74.55%
EBITDA
-CN¥249.23M
Revenue growth
6.46%
How to buy Sichuan Kelun-Biotech Biopharmaceutical from India
Indian residents can buy Sichuan Kelun-Biotech Biopharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Sichuan Kelun-Biotech Biopharmaceutical and place an order
Find Sichuan Kelun-Biotech Biopharmaceutical by name or by its ticker, 6990, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Sichuan Kelun-Biotech Biopharmaceutical trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Sichuan Kelun-Biotech Biopharmaceutical position in HKD and INR. Sichuan Kelun-Biotech Biopharmaceutical pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Sichuan Kelun-Biotech Biopharmaceutical from India
Trading and taxes when buying Sichuan Kelun-Biotech Biopharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneSichuan Kelun-Biotech Biopharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Sichuan Kelun-Biotech Biopharmaceutical stock?
Yes. Sichuan Kelun-Biotech Biopharmaceutical (6990) has been listed on the Hong Kong Stock Exchange since 2023, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Sichuan Kelun-Biotech Biopharmaceutical share cost in rupees?
One Sichuan Kelun-Biotech Biopharmaceutical share is HK$467.00 — about ₹5,714 at an HKD/INR rate of 12.23 on 25 Sep 2026. Both the Sichuan Kelun-Biotech Biopharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Sichuan Kelun-Biotech Biopharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Sichuan Kelun-Biotech Biopharmaceutical?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Sichuan Kelun-Biotech Biopharmaceutical shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Sichuan Kelun-Biotech Biopharmaceutical price. Paasa issues a capital-gains statement for your return.
Does Sichuan Kelun-Biotech Biopharmaceutical pay a dividend?
No. Sichuan Kelun-Biotech Biopharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Sichuan Kelun-Biotech Biopharmaceutical from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Sichuan Kelun-Biotech Biopharmaceutical a Hong Kong SAR China company, and does that change how it is taxed?
Sichuan Kelun-Biotech Biopharmaceutical trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Sichuan Kelun-Biotech Biopharmaceutical trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Sichuan Kelun-Biotech Biopharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Sichuan Kelun-Biotech Biopharmaceutical holding, its cost and its closing value.
How do I sell Sichuan Kelun-Biotech Biopharmaceutical and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.